(Total Views: 430)
Posted On: 08/12/2019 5:34:25 AM
Post# of 154854
Bristol-Myers Squibb just added a ccr5 arm to their study on Advanced Renal Cell Carcinoma.
Ccr5 arm added to
https://clinicaltrials.gov/ct2/history/NCT029...udyPageTop
BMS-813160, didn’t show up in my search because they didn’t list the Ccr5 until the recently or listed ccr2/5. They must be getting some results from the next two studies to add that arm. Theg have a monotherapy arm on the next one.
https://clinicaltrials.gov/show/NCT03184870
They also have been testing, With Advanced Solid Tumor in Colorectal Cancer & Pancreatic Cancer
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
And
https://clinicaltrials.gov/show/NCT03496662
BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Ccr5 arm added to
https://clinicaltrials.gov/ct2/history/NCT029...udyPageTop
BMS-813160, didn’t show up in my search because they didn’t list the Ccr5 until the recently or listed ccr2/5. They must be getting some results from the next two studies to add that arm. Theg have a monotherapy arm on the next one.
https://clinicaltrials.gov/show/NCT03184870
They also have been testing, With Advanced Solid Tumor in Colorectal Cancer & Pancreatic Cancer
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
And
https://clinicaltrials.gov/show/NCT03496662
BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
(0)
(0)
